Thursday, 10 November 2016

Survivin Immunotherapy - Buffalo, NY

This is the first I've heard of this experimental immunotherapy so I thought I'd share it with the group:

http://www.wndu.com/content/news/New-vaccine-for-brain-cancer-brings-hope-to-those-fighting-the-disease-400305491.html

If anyone has any further details, please mention it in the comments.
Posted by at
Labels: ,

6 comments:

  1. Stephen W10 November 2016 at 20:12

    Yes, the phase 2 trial results were published in August:
    https://www.ncbi.nlm.nih.gov/pubmed/27576783

    ReplyDelete
    Replies
    1. Stephen W10 November 2016 at 20:14

      That was for recurrent cases. The trial for newly diagnosed GBM is still recruiting:
      https://www.clinicaltrials.gov/ct2/show/NCT02455557

      Delete
    2. Stephen W10 November 2016 at 20:33

      In the trial for recurrent high-grade glioma, only 9 patients were treated, and 5 of these were secondary GBMs, one was anaplastic glioma, only 3 were primary GBM.

      Median OS from study entry was 86.6 weeks (20 months), impressive since these were all recurrent cases. But how much of that was due to the fact that these were mostly secondary GBM (IDH1-mutant?): we don't know (IDH status was not reported).

      Median PFS was 17.6 weeks (4 months) which is less impressive, and 3 patients maintained a partial response or stable disease for at least 6 months.

      So, it does seem to be effective for a subgroup of patients, but this group was rather heterogenous (primary and secondary GBM and anaplastic glioma, 1-3 prior recurrences, and some had had Avastin, while others hadn't). The newly diagnosed trial is recruiting around 50 patients, all with newly diagnosed GBM.

      Delete
    3. Winston11 November 2016 at 14:09

      Stephen

      I wrote you about a German peptide vaccine customized to a patients tumor gene expression. We are trying to figure-out what the difference in that vaccine and this Buffalo vaccine might be.

      Thanks
      Winston
      Brooklyn

      Delete
    4. Stephen W11 November 2016 at 19:04

      Hi Winston,
      Big difference: the CeGaT method involves identifying mutated proteins in the patients tumor and creating a vaccine composed of peptides (up to 15) containing those same mutations, which is a very personalized strategy.

      SurVaxM is by no means personalized, and targets a single tumor-associated protein (survivin) with a single peptide (SVN53-67/M57). This peptide conjugated to a vaccine adjuvant (KLH) makes the SurVaxM vaccine.

      The one method is personalized and multi-targeted (multiple peptides are used). The other is not personalized and single-targeted (only a survivin peptide is used).

      Delete
  2. SoDoWarts11 November 2016 at 09:04

    I just saw that today as well. I'm going to look into it here in Boston. Is anyone out there currently in this trial. I'd like to know how its going.

    ReplyDelete

Subscribe to: Post Comments (Atom)